WallStSmart

Assembly Biosciences Inc (ASMB)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 17085% more annual revenue ($12.22B vs $71.10M). VRTX leads profitability with a 35.5% profit margin vs -9.0%. VRTX trades at a lower P/E of 25.3x. VRTX earns a higher WallStSmart Score of 68/100 (B-).

ASMB

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.0Value: 5.7Quality: 7.0
Piotroski: 4/9Altman Z: -1.00

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASMBUndervalued (+34.0%)

Margin of Safety

+34.0%

Fair Value

$41.47

Current Price

$22.90

$18.57 discount

UndervaluedFair: $41.47Overvalued
VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASMB2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

ASMB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$485.32M3/10

Smaller company, higher risk/reward

P/E RatioValuation
306.1x2/10

Premium valuation, high expectations priced in

Return on EquityProfitability
-3.2%2/10

ROE of -3.2% — below average capital efficiency

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ASMB

The strongest argument for ASMB centers on Debt/Equity, Price/Book.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : ASMB

The primary concerns for ASMB are EPS Growth, Market Cap, P/E Ratio. A P/E of 306.1x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

ASMB profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.

ASMB carries more volatility with a beta of 1.09 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (68/100 vs 23/100), backed by strong 35.5% margins. ASMB offers better value entry with a 34.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Assembly Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?